Navigating Giant Cell Arteritis: Diagnosis, Management, and the Road Ahead - Episode 17
Reflecting on Trial Limitations in GCA: Painting a Future for IL-17A Targeting Therapies
Published on:
This video covers the following questions:
- Do these phase 3 results reflect the limitations of IL‑17A as a therapeutic target in GCA, or might issues in trial design, patient selection, or taper regimen explain the discrepancy between Phase II and Phase III outcomes? What role do you see for secukinumab in future GCA treatment?
